← All trials
NCT07132684
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 31, 2025
- Primary completion
- Aug 30, 2027
- Completion date
- Aug 30, 2028
- First posted
- Aug 20, 2025
- Last posted
- Oct 3, 2025
- Enrollment
- 240
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- China Academy of Chinese Medical SciencesLead sponsor
- People's Liberation Army of ChinaOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.